Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JANUARY 12, 2023

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.24100?guestAccessKey=4d302231-cf94-459f-a3bf-5300d83a7f3b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=011223

 

About The Study: Among outpatients with mild to moderate COVID-19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery in this randomized clinical trial that included 1,288 adults. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19. 

Authors: Susanna Naggie, M.D., M.H.S., of Duke University in Durham, North Carolina, is the corresponding author.

 

(doi:10.1001/jama.2022.24100)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.